Perspective Therapeutics to Participate at Upcoming May Investor Conferences

SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in the following upcoming investor conferences as scheduled below, and will be available for one-on-one meetings with investors.

Guggenheim Healthcare Talks | Radiopharmaceuticals Day
Date: Monday, May 13, 2024
Location: New York, NY

Format: Panel Discussion - Evolving Landscape of Radiopharmaceuticals in Industry
Time: Noon

Format: Company Presentation
Time: 2 p.m. ET

2024 RBC Capital Markets Global Healthcare Conference
Date: Wednesday, May 15, 2024
Location: New York, NY
Format: Fireside Chat
Time: 9.30 a.m. ET

Bank of America Health Care Conference 2024
Date: Wednesday, May 15, 2024
Location: Las Vegas, NV
Format: Fireside Chat
Time: 10 a.m. PT / 1 p.m. ET

Cantor’s Frontiers in Radiopharma Virtual Summit
Date: Monday, May 20, 2024
Location: Virtual
Format: Fireside Chat
Time: TBD

William Blair’s 3rd Virtual Radiopharma Conference
Date: Wednesday, May 22, 2024
Location: Virtual
Format: Fireside Chat
Time: 11 a.m. ET

Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website.

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.